1. Medtech Insight
  2. >>Policy & Regulation

Reimbursement Briefs: PillCam Reimbursement In Japan; 3-D Mammo Code Withdrawn; CMS Data Sharing

Japan will reimburse PillCam COLON. 3-D mammography CPT code application withdrawn from AMA CPT Editorial Panel meeting. CMS unveils new virtual research data-sharing tool.

Given Imaging Ltd. announced Nov. 11 that Japan’s Central Social Insurance Medical Council, Chuikyo, has approved its PillCam COLON for reimbursement, based on a recommendation by the Japanese Ministry of Health, Labor and Welfare. As of Jan. 1, each PillCam COLON capsule will be reimbursed in Japan for 83,100 yen, or approximately $840.00. In December, the Japanese MHLW will determine the final indication for use for PillCam COLON, an ingestible capsule that provides images of the colon, as well as the amount for the professional fee. Japan’s Pharmaceuticals & Medical Devices Agency granted regulatory clearance for PillCam COLON in July.

PillCam COLON received a CE mark in 2006 and is available in Europe, Israel, Asia, Latin America, Canada and Australia....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Policy & Regulation

US House Budget Sets FDA FY26 Funding At $3.2B

 
• By Sue Sutter and Derrick Gingery

A US House bill would give the FDA $33.1m more in budget authority than requested by the Trump Administration for fiscal year 2026. The measure was sent to the full House Appropriations committee on a party-line vote.

Panel: FDA’s Home Healthcare Initiative Holds Promise, But Challenges Remain

 
• By Elizabeth Orr

During a recent FDLI panel, experts discussed the FDA's Home Healthcare initiative, highlighting its potential benefits and challenges. Key issues include usability testing, reimbursement, labeling for home use, and the need for innovation while ensuring patient safety.

Where Do Questions Surrounding The EU’s AI Act Leave The Medtech Industry?

 
• By Amanda Maxwell

The EU’s Artificial Intelligence Act, which entered into force on 1 August 2024, is already facing turbulence.

Medtech Giants Brace for Tariffs Impact: Responses Range From Financial To Philosophical

 
• By Marion Webb, Shubham Singh, and Nancy Pham

Manufacturing shifts, financial planning, and supply chain changes are among the adjustments that medtech leaders are making to Trump-era tariffs. Medtech Insight’s review of first-quarter earnings calls reveals how firms are navigating the impact and uncertainty of evolving trade policies.

More from Medtech Insight

HistoSonics’ Edison System Gains Limited UK Access, While Awaiting CE Marking

 
• By Shubham Singh

While HistoSonics is awaiting the CE mark in Europe, it hit a major milestone by securing early limited market access in Great Britain under a Unmet Clinical Need Authorization (UCNA), bringing its noninvasive histotripsy treatment to patients with liver tumors.

Medtech Giants Brace for Tariffs Impact: Responses Range From Financial To Philosophical

 
• By Marion Webb, Shubham Singh, and Nancy Pham

Manufacturing shifts, financial planning, and supply chain changes are among the adjustments that medtech leaders are making to Trump-era tariffs. Medtech Insight’s review of first-quarter earnings calls reveals how firms are navigating the impact and uncertainty of evolving trade policies.

Global Medtech Guidance Tracker: May 2025

 
• By Vibha Sharma

Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Thirty-six documents have been posted on the tracker since its last update.